Core Insights - Genenta Science has announced a collaboration with Anemocyte to establish Cell Banks and produce Plasmids for viral vector production, marking a significant milestone in immuno-oncology therapies [1][2] Company Overview - Genenta Science is a clinical-stage immuno-oncology company focused on developing hematopoietic stem cell therapy for solid tumor cancers, with its lead product candidate being Temferon™ [5] - Anemocyte is a Biotech Manufacturing Organization based in Italy, specializing in the development and production of pDNA and mRNA, with over 25 years of experience in manufacturing innovative therapies [4] Collaboration Details - The partnership aims to leverage Genenta's innovative platform and Anemocyte's expertise in producing high-quality starting materials, which is crucial for advancing clinical trials [2][3] - Anemocyte's team has played a vital role in the manufacturing process, confirming the quality and reliability of their plasmid DNA for therapeutic products [3] Clinical Development - Genenta has completed a Phase 1 trial for newly diagnosed Glioblastoma Multiforme patients and has initiated a Phase 1/2a study for metastatic Renal Cell Carcinoma, which will include combinations with immune checkpoint inhibitors [5]